Metered-dose inhalers and insulin pens dispense in fixed, non-divisible units, canisters and pens, not in the tablet-by-tablet math a claims system expects by default. That mismatch is why these products generate a disproportionate share of findings in a PBM audit. A wrong days supply entry at the point of sale does not surface until it becomes part of a pattern across the PBM's claims book, inside a sample that gets extrapolated across the full lookback period. The exposure compounds from there. A documentation gap on one claim can become a recoupment demand covering every similar claim the pharmacy filed, and under a PBM's pattern-of-errors policy, a network termination proceeding.
How Days Supply Is Calculated For Inhalers
The methodology traces to CMS's own pharmacy self-auditing guidance for Medicaid program integrity, the Pharmacy Auditing and Dispensing Job Aid on billing other dosage forms. The formula multiplies the actuations or doses per canister by the number of canisters dispensed, then divides that total by the actuations or doses used each day. The job aid's example is a combination albuterol-ipratropium metered-dose inhaler labeled for 120 actuations per canister, dosed for chronic obstructive pulmonary disease at one inhalation four times daily. CMS flags that claim as a common target of billing-unit errors. Pharmacies record the quantity as 120 doses when the correct billing unit is the canister's metric weight, a mismatch that produces an audit finding even when the dispensing itself was correct.
Where Insulin Pens Break The Same Math
Insulin pens fail the same formula from the opposite direction. CMS's Medicare Prescription Drug Benefit Manual treats insulin pens, and the pen needles and supplies dispensed with them, as medical supplies that can satisfy the definition of a Part D drug, a category the manual lists separately from the insulin itself. A pen dispenses as a whole unit, and a pharmacy cannot split a partially used pen across two fills the way it can split a tablet bottle. When a prescriber's sliding-scale or titrating dosage, common with insulin, changes the daily unit count mid-therapy, the days supply on file reflects the dose at fill, not the dose the patient is using by the time the pen runs out. Days supply calculated from the labeled starting dose will not match that use unless the pharmacy's record documents the titrated dose instead.
Documenting The Prescribed Regimen, Not The Label Default
The sig code on the original prescription, not the FDA-labeled starting dose, is what the days supply calculation should reflect. A prescriber's climbing or stepping-down titration schedule belongs on the prescription record the pharmacy keeps, not only on the claim. The same discipline carries across PBMs. Signature log gaps are the most common finding pharmacies dispute in Capital Rx audits, and a CarelonRx recoupment demand can escalate to a Special Investigations Unit referral once a documentation gap looks like a pattern rather than an error. A single days supply mismatch on an inhaler or pen claim is a billing correction the pharmacy fixes on appeal. A pattern of them across a product line is what turns a routine recoupment into that kind of referral.
From One Flagged Claim To A Sample-Wide Recoupment
A single inhaler or insulin pen claim with a days supply that does not match the documented regimen rarely stays a single claim. A pattern of inhaler or insulin pen discrepancies across a COPD-heavy or diabetes-heavy patient panel is what turns a PBM's review into an investigative audit, which then extrapolates the sample's error rate across every claim for that product in the lookback period. One miscalculated refill can become a recoupment demand covering years of dispensing. Challenging that demand on audit appeal means reconstructing the prescribed regimen claim by claim, exactly the documentation that was missing when the claim was first flagged.
CMS's own pharmacy audit guidance calculates an inhaler's days supply by dividing total actuations dispensed by actuations used per day, not by the units-per-tablet default most claims systems automate.
Health Law Alliance has represented 2,500+ clients nationwide.
Why Early Legal Counsel Is Critical
It is critical that pharmacies promptly retain experienced healthcare defense counsel upon receiving a PBM audit notice, a days supply discrepancy finding, or a related recoupment demand. Early legal intervention can protect the pharmacy's rights, shape the documentation record before a sample hardens into an extrapolated demand, help avoid inadvertent admissions during the audit response, and allow counsel to communicate with the PBM on the pharmacy's behalf. Delaying legal representation can lengthen the audit, increase the eventual recoupment, and expose the pharmacy to unnecessary risk.
How Health Law Alliance Can Help
If a PBM has flagged your pharmacy's inhaler or insulin pen claims for a days supply discrepancy, Health Law Alliance's PBM audit defense attorneys can review the prescribed regimen, the claims record, and the PBM's extrapolation methodology before the response deadline runs. Contact Health Law Alliance for a free, confidential consultation.
